8-KItem 2.02 · Results of OperationsItem 9.01 · Financial Statements
AbbVie Inc. (ABBV)

AbbVie includes $216 million expense in Q3 and lowers 2026 EPS guidance

Filed with the SEC on · Summarized by InvestorsBot

AbbVie said third-quarter 2026 results are expected to include $216 million of pre-tax acquired in-process research and development and milestone expense, reducing adjusted diluted EPS by $0.11 to a projected $3.73-$3.77. Including the expense, AbbVie’s 2026 adjusted diluted EPS guidance is $13.76-$13.96, down from the previously announced $13.87-$14.07 range; final results remain subject to closing procedures.

Read the original filing on SEC EDGAR

Get summaries like this in your inbox every morning

Pick up to 20 companies — we read their SEC filings overnight and send you the plain-English version. Free.

Subscribe free

More from AbbVie Inc.

AbbVie Completes $10 Billion Debt Offering to Fund Apogee Acquisition

8-K · August 18, 2026

AbbVie EVP Nicholas Donoghoe sells $8.2M in stock

Form 4 · Insider Trade · August 18, 2026

AbbVie launches $10 billion bond offering to fund Apogee acquisition

8-K · August 5, 2026

AbbVie reports 10.2% revenue growth and agrees to acquire Apogee for $10.9 billion

8-K · July 31, 2026

AbbVie 8-K (Item 9.01) — Supplemental Indenture No.

8-K · March 4, 2026

On Mar 4, 2026 AbbVie completed an $8.0B notes offering: $750M floating-rate due 2028; $1.5B 3.775% due…

8-K · March 4, 2026